

Title (en)  
COMBINATION CANCER THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT

Title (de)  
KOMBINATIONSKREBSTHERAPIE UND CYTOKINKONTROLLTHERAPIE ZUR KREBSBEHANDLUNG

Title (fr)  
ASSOCIATION D'UNE CANCÉROTHÉRAPIE ET D'UNE THÉRAPIE DE CONTRÔLE DES CYTOKINES POUR LE TRAITEMENT DU CANCER

Publication  
**EP 4031655 A4 20240529 (EN)**

Application  
**EP 20865932 A 20200916**

Priority

- US 201916576676 A 20190919
- IL 2020051011 W 20200916
- US 201562117752 P 20150218

Abstract (en)  
[origin: CA3151815A1] Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also methods for slowing, reducing, inhibiting, or eliminating metastatic spread of a cancer or a tumor in a subject, comprising administering a combination therapy comprising an early apoptotic cell population and one or more cancer therapeutic agents.

IPC 8 full level  
**C12N 5/078** (2010.01); **A61K 39/00** (2006.01); **C07K 16/30** (2006.01); **C07K 19/00** (2006.01)

CPC (source: EP IL KR US)  
**A61K 39/39541** (2013.01 - IL KR); **A61K 39/39558** (2013.01 - EP IL KR); **A61K 39/4611** (2023.05 - EP IL KR US);  
**A61K 39/4631** (2023.05 - EP IL KR US); **A61K 39/464406** (2023.05 - EP IL KR US); **A61K 39/464412** (2023.05 - EP IL KR US);  
**A61K 39/464419** (2023.05 - EP IL KR US); **A61K 45/06** (2013.01 - EP IL KR); **A61K 2239/31** (2023.05 - US); **A61K 2239/38** (2023.05 - US);  
**A61K 2239/48** (2023.05 - US); **A61K 2239/59** (2023.05 - US); **A61P 35/00** (2018.01 - KR); **A61P 35/04** (2018.01 - EP IL);  
**A61P 37/06** (2018.01 - EP IL KR); **C07K 14/7051** (2013.01 - EP IL); **C07K 16/2887** (2013.01 - EP IL KR); **C12N 5/0636** (2013.01 - EP IL KR US);  
**A61K 2039/505** (2013.01 - EP IL KR); **A61K 2239/31** (2023.05 - EP IL KR); **A61K 2239/38** (2023.05 - EP IL KR);  
**A61K 2239/48** (2023.05 - EP IL KR); **A61K 2239/59** (2023.05 - EP IL KR); **A61K 2300/00** (2013.01 - IL KR); **C07K 16/2803** (2013.01 - EP);  
**C07K 2317/24** (2013.01 - EP); **C07K 2317/622** (2013.01 - EP IL); **C12N 2501/04** (2013.01 - IL KR); **C12N 2501/91** (2013.01 - EP IL KR);  
**C12N 2510/00** (2013.01 - EP IL); **C12N 2523/00** (2013.01 - IL KR); **C12N 2529/00** (2013.01 - EP IL KR)

C-Set (source: EP)  
**A61K 39/39558 + A61K 2300/00**

Citation (search report)  
No further relevant documents disclosed

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
AU 2020350221 A1 20220331; CA 3151815 A1 20210325; EP 4031655 A2 20220727; EP 4031655 A4 20240529

DOCDB simple family (application)  
AU 2020350221 A 20200916; CA 3151815 A 20200916; EP 20865932 A 20200916